- Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat Fierce Biotech
- Geron Stock Is Soaring After Hours: What's Going On? Yahoo Finance
- Geron’s stock soars 95% after FDA panel votes in favor of blood-disorder drug MarketWatch
- Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes 2 Minute Medicine
- FDA ODAC Votes in Favor of Imetelstat Benefits Vs Risks in Lower-Risk MDS Cancer Network
Friday, March 15, 2024
Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat - Fierce Biotech
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment